Johnson & Johnson (JNJ) vs Merck & Co., Inc. (MRK)
- Johnson & Johnson JNJ 273.30 +0.36%
- Merck & Co., Inc. MRK 147.11 +0.12%
Johnson & Johnson and Merck & Co., Inc. are both Drug Manufacturers General companies. Johnson & Johnson is the larger, with a market value of $655.6B against $362.5B — 1.8× the size. Johnson & Johnson trades at the lower P/E: 41.3× against 118×. Johnson & Johnson grew revenue faster over the last twelve months: 7.80% against 4.89%. Johnson & Johnson has the higher net margin (16.2% vs 3.64%) and the higher return on invested capital (11.1% vs 0.00%). Both pay a dividend; Merck & Co., Inc. yields more (2.31% vs 1.94%). Across the 23 metrics below, Johnson & Johnson leads on 14 and Merck & Co., Inc. on 9.
Valuation
Profitability
| Metric | JNJ | MRK | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 67.56% | 71.75% | 73.01% |
| Operating margin | 19.72% | 9.20% | 18.34% |
| Net margin | 16.20% | 3.64% | 7.31% |
| Free cash flow margin | 21.13% | 0.00% | 18.52% |
| Return on equity | 20.02% | 0.00% | 5.80% |
| Return on assets | 8.25% | 0.00% | 2.28% |
| Return on invested capital | 11.07% | 0.00% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack